The US Food and Drug Administration has approved the first biologic therapy for atopic dermatitis, the itchy skin condition better known as eczema. The drug is a human monoclonal antibody called Dupixent (dupilumab) that targets the interleukin-4 (IL-4) receptor alpha subunit, thereby blocking the signaling of two pro-inflammatory cytokines—IL-4 and IL-13—both of which are key mediators of the T helper type 2 (TH2) immune response, thought to be the main driver of the disease…
Para acessar a publicação na íntegra clique aqui
Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 5 MAY 2017 391, 392